Literature DB >> 26366014

2-Allylaminothiazole and 2-allylaminodihydrothiazole derivatives: synthesis, characterization, and evaluation of bioactivity.

Renata Studzińska1, Aleksandra Karczmarska-Wódzka2, Anna Kozakiewicz3, Renata Kołodziejska2, Renata Paprocka1, Marcin Wróblewski2, Beata Augustyńska2, Bożena Modzelewska-Banachiewicz1.   

Abstract

ABSTRACT: Some reactions of selected chlorooxoesters and haloesters with a 1-allylthiourea under various conditions have been performed. The reactions have been performed in methanol in alkaline and neutral environment. Condensation of 1-allylthiourea with chlorooxoesters has been further led via acetal as intermediate compound. As a result, the compounds containing thiazole and a 4,5-dihydrothiazole ring with a good yield have been obtained. The structures of the compounds were verified by 1H NMR, 13C NMR as well as X-ray diffraction analysis. Due to the potential biological activity of the synthesized compounds, the parameters of their bioavailability have been determined, and the probability of pharmacological action has been defined. All of the obtained compounds fulfilled the rule of five, which indicate their good absorption after oral intake. The probability of pharmacological action and potential targets calculated for the obtained compounds show that they can be potential drugs.

Entities:  

Keywords:  Heterocycles; Organic synthesis; Structure–activity relationships; Thiazole derivatives; X-ray structure determination

Year:  2015        PMID: 26366014      PMCID: PMC4559095          DOI: 10.1007/s00706-015-1539-z

Source DB:  PubMed          Journal:  Monatsh Chem        ISSN: 0026-9247            Impact factor:   1.451


Introduction

The thiazole and 4,5-dihydrothiazole derivatives exhibit promising biological activity. The attention should be paid to, among others, biovitrum BVT-2733, biovitrum BVT-14225 [1-4], and amgen 2922 [4-6], which are described as inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (Fig. 1). 11β-Hydroxysteroid dehydrogenase type 1 regulates glucocorticoid action, and the inhibition of this enzyme is a viable therapeutic strategy for the treatment of type 2 diabetes and the metabolic syndrome. Furthermore, compounds containing a thiazole ring are used as inhibitors of thymidylate synthase [7, 8]. Due to their biological activity, it is worth concentrating on the efficient method of the thiazole and dihydrothiazole ring formation.
Fig. 1

11β-Hydroxysteroid dehydrogenase type 1 inhibitors containing a thiazole and dihydrothiazole ring

11β-Hydroxysteroid dehydrogenase type 1 inhibitors containing a thiazole and dihydrothiazole ring One of the ways of forming a dihydrothiazole ring is the reaction of thiourea or its derivatives with haloacids. Such reactions have been described before [9, 10]. They have been carried out in various solvents, i.e., water, pyridine, benzene, and acetonitrile. The obtained products had the form of hydrogen halides. To obtain dihydrothiazoles, hydrogen halides were treated in alkaline conditions: sodium carbonate or aqueous solution of ammonia. Due to the previously conducted condensation reactions of 1-allylthiourea (1) with oxoesters in alkaline conditions, which have allowed us to obtain the N-allylthiouracil derivatives [11, 12], we have become interested in carrying out the reactions of haloesters with 1 in similar conditions. Encouraged by high efficiency of the synthesized products as well as the easiness of their extracting, we have expanded the conducted synthesis applying chlorooxoesters.

Results and discussion

Chemistry

The condensation reactions for three different haloesters 2–4 were carried out in alkaline conditions (Table 1). The reaction of 1 with haloesters was carried out in methanol with a 10 % excess of ester and a double excess of sodium methoxide (procedure A). The products were extracted in a yield of 50–65 %. Additionally, the analogous reactions without the base afforded products 6 and 7 in lower yields (40–47 %), whereas only trace amounts of product 5 were obtained from ester 2 (procedure B). The structures of 5–7 were verified by 1H and 13C NMR spectral data, as well as mass spectra. The structures of 5 and 7 were also verified by X-ray diffraction analysis (Fig. 2).
Table 1

The condensation reaction of 1 with 2-haloesters 2-4

No.XR1 Procedurea Time/hYield of 57/%M.p. of 5–7/°C
2 ClHAB82450Trace89–90b
3 BrCH3 AB11684775–76
4 BrC2H5 AB32654077–78

aProcedure A: MeOH, MeONa, the boiling point; procedure B: EtOH, the boiling point

bRef. [9] 102–103 °C

Fig. 2

X-ray structure of 5 (left) and 7 (right)

The condensation reaction of 1 with 2-haloesters 2-4 aProcedure A: MeOH, MeONa, the boiling point; procedure B: EtOH, the boiling point bRef. [9] 102–103 °C X-ray structure of 5 (left) and 7 (right) The above-mentioned highly selective reactions in a good yield in alkaline conditions have encouraged us to carry out the analogous reactions with the use of 1 and chlorooxoesters. The condensation reactions of 1 with 3-oxoesters lead to the formation of 3-allyl-2-thiouracil (Fig. 3) [13, 14]. The presence of a chlorine atom in the oxoester molecules 9 and 10 causes a carbonyl group and a halogen atom to be involved in the reaction, while an ester group is not (Fig. 3; Table 2). Furthermore, the nucleophilic substitution reaction occurs on the sulfur atom, but does not occur on the nitrogen atom, as in the case of addition elimination reaction in the ester group of a 3-oxoester molecule. Consequently, a five (not six)-membered ring containing nitrogen and sulfur atom is formed, in the same way as while using haloesters 2–4 (Table 1). As a result of addition of 1 to the carbonyl group of chlorooxoester, and then the elimination of water, the cyclic products 11, 12, containing not one but two double bonds in the ring, were formed.
Fig. 3

The reaction of 1 with 3-oxoesters, chlorooxoesters, and haloesters

Table 2

The condensation reaction of 1 with chlorooxoesters

No.R2 R3 Procedurea Time/hYield of 1112/%M.p. of 1112/ °C
9 CH3 COOC2H5 ABC381144282104–105b
10 CH2COOC2H5 HABC131115356042–43

aProcedure A: MeOH, MeONa, procedure B: EtOH, procedure C: step 1—MeOH, HC(OCH3)3, step 2—EtOH, H2SO4

bRef. [15] 70–73 °C, Ref. [16] 109–110 °C

The reaction of 1 with 3-oxoesters, chlorooxoesters, and haloesters The condensation reaction of 1 with chlorooxoesters aProcedure A: MeOH, MeONa, procedure B: EtOH, procedure C: step 1—MeOH, HC(OCH3)3, step 2—EtOH, H2SO4 bRef. [15] 70–73 °C, Ref. [16] 109–110 °C The reaction of 1 with chlorooxoesters and haloesters was carried out at the same alkaline conditions (procedure A). In the first case the products were obtained with a much lower yield (4–15 %), which is probably due to two simultaneous condensation reactions: aldol and Claisen condensation reaction (Table 2). The poor yield of products 11 and 12 made us change the conditions of conducting the reactions. The reaction of 1 with chlorooxoesters in ethanol let us obtain products 11 and 12 in higher yields (35–42 %) (procedure B). A further increase of a yield was obtained due to transforming a carbonyl group into acetal, followed by the reaction of obtained acetals from 1 in acidic environment, according to the procedure described above (procedure C) [14]. The structures of 11 and 12 were verified by 1H and 13C NMR spectral data, mass spectra, as well as X-ray diffraction analysis (Fig. 4).
Fig. 4

X-ray structure of 11 (left) and 12 (right)

X-ray structure of 11 (left) and 12 (right)

Evaluation of biological activity

Due to the biological activity of the compounds containing thiazole and dihydrothiazole rings [1-8], we have calculated the parameters conditioning the bioavailability of the synthesized compounds and their probable activity. Lipinski’s rule of five describes molecular properties important for drug pharmacokinetics in the human body, especially their oral absorption. The rule says, that an orally active drug must not violate more than one of the following criteria: ≤5 hydrogen donors (nOHNH), ≤10 hydrogen acceptors (nON), MW ≤ 500 Da, log Pcalc ≤5 [17]. Those properties calculated with Molinspiration program [18] are presented in the Table 3. All compounds 2–4, 11, 12 fulfilled the rule of five, which indicate their good absorption after oral intake.
Table 3

The value of molecular weight, miLogP, hydrogen donors and acceptors, and TPSA calculated by Molinspiration program

5 6 7 11 12
Molecular weight156.21170.24184.26226.30226.30
miLogP 0.3610.7241.2261.5272.150
nOHNH11121
nON33344
TPSA/Å2 41.4641.4641.4662.2351.22
The value of molecular weight, miLogP, hydrogen donors and acceptors, and TPSA calculated by Molinspiration program Topological polar surface area (TPSA) becomes another popular indicator of drug absorbance [19]. TPSA values lower than 140 Å2 suggest good cell membrane permeability of derivatives 2-4 and 11, 12. Moreover, calculated TPSA values below 60 Å2 suggest high chances to penetrate blood–brain barrier for compounds 2–4 and 12. The probability of pharmacological action and potential targets for compounds 2–4 and 11, 12 were calculated by PASS online program [20], which is based on analysis of structure–activity relationships (SAR) of chemical compounds and predicts over 4000 kinds of biological activities, including pharmacological effects, mechanisms of action, toxic and adverse effects with average accuracy above 95 % [21]. The selected results of the predicted activities and mechanisms of action of 2–4 and 11, 12 are presented in Table 4.
Table 4

Probabilities of biological activity and action mechanisms for compounds 5–7, 11, 12

Pa/%
5 6 7 11 12
Pharmacological actionAntieczematic36.640.255.668.589.6
Mucomembranous protector78.555.761.662.583.2
Antiulcerative55.653.729.865.975.2
Antiviral49.960.157.252.966.3
Radioprotector46.165.767.4np21.4
Mechanism of actionChloride peroxidase inhibitor71.061.852.043.9np
Muramoyltetrapeptide carboxypeptidase inhibitor35.030.430.949.875.5
Membrane permeability inhibitor67.155.245.568.946.6
Cl-transporting ATPase inhibitor67.759.454.343.136.2
Gastrin inhibitor66.669.360.755.951.5

np Not predicted

Probabilities of biological activity and action mechanisms for compounds 5–7, 11, 12 np Not predicted The best results were obtained for derivative 12, which showed the highest probabilities for the mucomembranous protection, antieczematic, antiulcerative, and antiviral activity. The predictions for compounds 2–4 and 12 showed that they are also possible mucomembranous protectors. Moreover, derivatives 3, 4 may be radioprotectors and may have antiviral activity. According to PASS calculations a possible mechanism of action for compounds 2–4 and 11, 12 is enzymes inhibition: chloride peroxidase, muramoyltetrapeptide carboxypeptidase, Cl−-transporting ATPase. Other mechanisms of membrane permeability and gastrin inhibitions should be associated with mucomembranous protection and antiulcerative activity, respectively.

Conclusion

In conclusion, we have successfully conducted simple synthesis leading to the compounds containing thiazole and 4,5-dihydrothiazole ring in the reaction of 1-allylthiourea with haloesters and oxoesters, respectively. By changing the reaction conditions we have managed to obtain the products of a very good performance. The method is very universal and can be applied for the synthesis of compounds containing thiazole and dihydrothiazole rings.

Experimental

1H NMR and 13C NMR spectra were recorded on Bruker 300 MHz, 400 MHz, and 700 MHz apparatus (TMS as an internal standard). MS spectra were recorded on the Finnigan MAT 95. UV spectra were recorded on the spectrophotometer Aquarius 7250 Cecil Instruments. All chemicals and solvents were purchased commercially and used without further purification. The progress of reactions and also the purity of the obtained compounds were monitored by TLC on TLC-sheets ALUGRAM SIL G/UV254 plates with ethyl acetate as an eluent.

General procedures for the synthesis of compounds 5–7, 11, 12

Procedure A

To a solution of sodium methoxide (prepared from 0.1 mol of sodium in 60 cm3 anhydrous MeOH), 0.05 mol of 1 and 0.055 mol of ester (2–4, 9, 10) were added and refluxed (reflux time depends on the compounds present in Tables 1, 2). The solvent was evaporated and the residue was dissolved in water and neutralized with HCl to pH 7–8. The product was extracted with CHCl3, dried, concentrated, and crystallized from diethyl ether.

Procedure B

To a solution of 30 cm3 anhydrous EtOH, 0.05 mol of 1 and 0.055 mol of ester (2–4, 9, 10) were added and refluxed (reflux time depends on the compounds present in Tables 1, 2). The solvent was evaporated and the residue was dissolved in water and neutralized with NaOH to pH 7–8. The product was extracted with CHCl3, dried, concentrated, and crystallized from diethyl ether.

Procedure C

To a solution of 30 cm3 anhydrous MeOH, 0.03 mol of triethyl orthoformate, 0.075 g p-toluenesulfonic acid and 0.05 mol of chlorooxoester 9 or 10 were added and mixed for 24 h. Diethyl ether (30 cm3) was added to the mixture and neutralized with sodium ethoxide to pH 7–8, then 30 cm3 distilled water was added. The product was extracted with diethyl ether and dried with sodium carbonate. The solvent was evaporated and to the residue 0.02 mol of 1, and 0.11 cm3 of concentrated sulfuric acid were added and refluxed for 1 h. The solvent was evaporated and the residue was dissolved in 30 cm3 water and neutralized with NaOH to pH 7–8. The product was extracted with CHCl3, dried, concentrated, and crystallized from diethyl ether.

2-(Allylamino)thiazol-4(5H)-one (5, C6H8N2OS)

M.p.: 89–90 °C; UV (H2O + 5 % EtOH): λmax (ε × 103) = 191 (0.75), 230.5 (2.22) nm (mol−1 dm3 cm−1); 1H NMR (CDCl3): δ = 3.83 (s, 2H, CH2), 3.94 (t, J = 1.4 Hz, 1H, NH), 3.96 (dd, J = 1.4, 5.6 Hz, 2H, CH2=CH–CH), 5.24 (dd, J = 2.1, 10.5 Hz, 1H, CHHB=CH–CH2), 5.31 (dd, J = 2.1, 17.5 Hz, 1H, CHAH=CH–CH2), 5.90 (m, 1H, CH2=CH–) ppm; 13C NMR (100 MHz, CDCl3): δ = 185.8, 183.8, 131.7, 118.6, 47.1, 38.7 ppm; MS (CI, isobutane): m/z (%) = 157 ([M + 1]+, 100).

2-(Allylamino)-5-methylthiazol-4(5H)-one (6, C7H10N2OS)

M.p.: 75–76 °C; UV (H2O + 5 % EtOH): λmax (ε × 103) = 192.5 (0.97), 231 (2.19) nm (mol−1 dm3 cm−1); 1H NMR (CDCl3): δ = 1.61 (d, J = 7.0 Hz, 2H, C–CH3), 3.91 (t, J = 1.4 Hz, 1H, NH), 3.93 (dd, J = 1.4, 5.6 Hz, 2H, CH2=CH–CH), 4.08 (q, J = 7.0 Hz, CH–CH3), 5.23 (dd, J = 1.4, 10.5 Hz, 1H, CHHB=CH–CH2), 5.31 (dd, J = 1.4, 17.5 Hz, 1H, CHAH=CH–CH2), 5.90 (m, 1H, CH2=CH–) ppm; 13C NMR (100 MHz, CDCl3): δ = 189.0, 182.2, 131.7, 118.5, 49.6, 47.2, 19.0 ppm; MS (CI, isobutane): m/z (%) = 171 ([M + 1]+, 100).

2-(Allylamino)-5-ethylthiazol-4(5H)-one (7, C8H12N2OS)

M.p.: 77–78 °C; UV (H2O + 5 % EtOH): λmax (ε × 103) = 192 (0.85), 231.5 (2.31) nm (mol−1 dm3 cm−1); 1H NMR (CDCl3): δ = 0.99 (dt, J = 2.8, 7.0 Hz, 3H, CH–CH2–CH), 2.00 (dq, J = 2.8, 4.2 Hz, 2H, CH–CH–CH3), 3.95 (dd, J = 1.4, 5.6 Hz, 2H, CH2=CH–CH), 4.09 (t, J = 1.4 Hz, 1H, NH), 4.18 (tq, J = 4.2, 7.0 Hz, CH–C2H5), 5.23 (dd, J = 1.4, 10.5 Hz, 1H, CHHB=CH–CH2), 5.30 (dd, J = 1.4, 17.5 Hz, 1H, CHAH=CH–CH2), 5.94 (m, 1H, CH2=CH–) ppm; 13C NMR (100 MHz, CDCl3): δ = 188.0, 182.6, 131.8, 118.4, 57.4, 47.3, 26.2, 11.5 ppm; MS (CI, isobutane): m/z (%) = 185 ([M + 1]+, 100).

Ethyl 2-(allylamino)-4-methylthiazole-5-carboxylate (11, C10H14N2O2S)

M.p.: 104–105 °C; UV (H2O + 5 % EtOH): λmax (ε × 103) = 216 (9.77), 308 (17.73) nm (mol−1 dm3 cm−1); 1H NMR (CDCl3): δ = 1.32 (t, J = 6.9 Hz, 3H, OCH2CH), 1.87 (1H, NH), 2.51 (s, 3H, C4–CH), 3.88 (d, J = 5.2 Hz, 2H, CH2=CH–CH), 4.25 (q, J = 7.1 Hz, 2H, OCHCH3), 5.23 (dd, 1H, J = 1.5, 10.2 Hz, CHHB=CH–CH2), 5.33 (dd, J=1.5, 17.3 Hz, 1H, CHAH=CH–CH2), 5.88 (m, 1H, CH2=CH–) ppm; 13C NMR (100 MHz, CDCl3): δ = 171.6, 162.7, 159.4, 132.5, 117.7, 109.3, 60.4, 48.3, 17.4, 14.5 ppm; MS (CI, isobutane): m/z (%) = 227 ([M + 1]+, 100).

Ethyl 2-[2-(allylamino)thiazol-4-yl]acetate (12, C10H14N2O2S)

M.p.: 42–43 °C; UV (H2O + 5 % EtOH): λmax (ε × 103) = 261 (7.55) nm (mol−1 dm3 cm−1); 1H NMR (CDCl3): δ = 1.28 (t, J = 6.9 Hz, 3H, OCH2CH), 1.93 (1H, NH), 3.57 (d, J = 0.9 Hz, 2H, CHOCH2CH3), 3.86 (d, J = 5.2 Hz, 2H, CH2=CH–CH), 4.21 (q, J = 6.9 Hz, 2H, OCHCH3), 5.20 (dd, J = 1.5, 11.1 Hz, 1H, CHHB=CH–CH2), 5.31 (dd, J=1.5, 17.4 Hz, 1H, CHAH=CH–CH2), 5.91 (m, 1H, CH2=CH–), 6.34 (t, J = 0.9 Hz, 1H, C5H) ppm; 13C NMR (100 MHz, CDCl3): δ = 170.5, 169.7, 145.0, 133.5, 117.2, 103.6, 60.9, 48.3, 37.4, 14.2 ppm; MS (70 eV): m/z = 226 ([M + 1]+, 100).

X-ray diffraction study

The X-ray data for reported structures were collected at 293(2) K with an Oxford Sapphire CCD diffractometer using MoKα radiation λ = 0.71073 A and ω-2θ method. The numerical absorption corrections were applied (RED171 package of programs Oxford Diffraction, 2000) [22]. All structures have been solved by direct methods and refined with the full-matrix least-squares method on F2 with the use of SHELX-97 program package [23]. The hydrogen atoms have been located from the different electron density maps and constrained during refinement. The crystallographic data have been deposited with the Cambridge Crystallographic Data Centre, the CCDC numbers: 1034864 for 5 and 1034865–1034867 for 7, 11, and 12, respectively.
  9 in total

1.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.

Authors:  P Ertl; B Rohde; P Selzer
Journal:  J Med Chem       Date:  2000-10-05       Impact factor: 7.446

2.  Quinazoline antifolate thymidylate synthase inhibitors: heterocyclic benzoyl ring modifications.

Authors:  P R Marsham; L R Hughes; A L Jackman; A J Hayter; J Oldfield; J M Wardleworth; J A Bishop; B M O'Connor; A H Calvert
Journal:  J Med Chem       Date:  1991-05       Impact factor: 7.446

3.  A short history of SHELX.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A       Date:  2007-12-21       Impact factor: 2.290

4.  2-(S)-phenethylaminothiazolones as potent, orally efficacious inhibitors of 11beta-hydroxysteriod dehydrogenase type 1.

Authors:  David J St Jean; Chester Yuan; Eric A Bercot; Rod Cupples; Michelle Chen; Jenne Fretland; Clarence Hale; Randall W Hungate; Renee Komorowski; Murielle Veniant; Minghan Wang; Xiping Zhang; Christopher Fotsch
Journal:  J Med Chem       Date:  2007-02-08       Impact factor: 7.446

5.  3D-QSAR studies on quinazoline antifolate thymidylate synthase inhibitors by CoMFA and CoMSIA models.

Authors:  Vivek Srivastava; S P Gupta; M I Siddiqi; B N Mishra
Journal:  Eur J Med Chem       Date:  2010-01-13       Impact factor: 6.514

6.  Structural characterization and pharmacodynamic effects of an orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor.

Authors:  Clarence Hale; Murielle Véniant; Zhulun Wang; Michelle Chen; Jocelyn McCormick; Rod Cupples; Dean Hickman; Xiaoshan Min; Athena Sudom; Haoda Xu; Guy Matsumoto; Christopher Fotsch; David J St Jean; Minghan Wang
Journal:  Chem Biol Drug Des       Date:  2007-12-07       Impact factor: 2.817

7.  The discovery of 2-anilinothiazolones as 11beta-HSD1 inhibitors.

Authors:  Chester Yuan; David J St Jean; Qingyian Liu; Lynn Cai; Aiwen Li; Nianhe Han; George Moniz; Ben Askew; Randall W Hungate; Lars Johansson; Lars Tedenborg; David Pyring; Meredith Williams; Clarence Hale; Michelle Chen; Rod Cupples; Jiandong Zhang; Steven Jordan; Michael D Bartberger; Yaxiong Sun; Maurice Emery; Minghan Wang; Christopher Fotsch
Journal:  Bioorg Med Chem Lett       Date:  2007-09-25       Impact factor: 2.823

8.  2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.

Authors:  Lars Johansson; Christopher Fotsch; Michael D Bartberger; Victor M Castro; Michelle Chen; Maurice Emery; Sonja Gustafsson; Clarence Hale; Dean Hickman; Evert Homan; Steven R Jordan; Renee Komorowski; Aiwen Li; Kenneth McRae; George Moniz; Guy Matsumoto; Carlos Orihuela; Gunnar Palm; Murielle Veniant; Minghan Wang; Meredith Williams; Jiandong Zhang
Journal:  J Med Chem       Date:  2008-04-18       Impact factor: 7.446

9.  Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1.

Authors:  Tjeerd Barf; Jerk Vallgårda; Rikard Emond; Charlotta Häggström; Guido Kurz; Alf Nygren; Vivienne Larwood; Erifili Mosialou; Kent Axelsson; Rolf Olsson; Lars Engblom; Naimie Edling; Yuko Rönquist-Nii; Birgitta Ohman; Peteris Alberts; Lars Abrahmsén
Journal:  J Med Chem       Date:  2002-08-29       Impact factor: 7.446

  9 in total
  3 in total

1.  A Novel N-Tert-Butyl Derivatives of Pseudothiohydantoin as Potential Target in Anti-Cancer Therapy.

Authors:  Daria Kupczyk; Renata Studzińska; Szymon Baumgart; Rafał Bilski; Tomasz Kosmalski; Renata Kołodziejska; Alina Woźniak
Journal:  Molecules       Date:  2021-04-29       Impact factor: 4.411

2.  Design, Synthesis and Antifungal Activity Evaluation of New Thiazolin-4-ones as Potential Lanosterol 14α-Demethylase Inhibitors.

Authors:  Anca Stana; Dan C Vodnar; Radu Tamaian; Adrian Pîrnău; Laurian Vlase; Ioana Ionuț; Ovidiu Oniga; Brînduşa Tiperciuc
Journal:  Int J Mol Sci       Date:  2017-01-17       Impact factor: 5.923

3.  Synthesis of Novel 2-(Isopropylamino)thiazol-4(5H)-one Derivatives and Their Inhibitory Activity of 11β-HSD1 and 11β-HSD2 in Aspect of Carcinogenesis Prevention.

Authors:  Daria Kupczyk; Renata Studzińska; Rafał Bilski; Szymon Baumgart; Renata Kołodziejska; Alina Woźniak
Journal:  Molecules       Date:  2020-09-15       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.